ES2431914B2 - Anticuerpo monoclonal humano ANTI-HER2 - Google Patents

Anticuerpo monoclonal humano ANTI-HER2 Download PDF

Info

Publication number
ES2431914B2
ES2431914B2 ES201200465A ES201200465A ES2431914B2 ES 2431914 B2 ES2431914 B2 ES 2431914B2 ES 201200465 A ES201200465 A ES 201200465A ES 201200465 A ES201200465 A ES 201200465A ES 2431914 B2 ES2431914 B2 ES 2431914B2
Authority
ES
Spain
Prior art keywords
her2
monoclonal antibody
human monoclonal
human
her2 human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201200465A
Other languages
English (en)
Other versions
ES2431914A1 (es
Inventor
Iván SANCHEZ DE MELO
Enrique VILLEGAS MARTÍNEZ
Jorge BOLIVAR PÉREZ
Laura HERNÁNDEZ RUIZ
Carmen Castro González
Francisco José GARCIA COZAR
Carlos PENDÓN MELÉNDEZ
Jesús Manuel CANTORAL FERNÁNDEZ
Francisco Javier FERNÁNDEZ ACERO
Carlos GARRIDO CRESPO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curaxys Sl
CURAXYS S L
Universidad de Cadiz
Original Assignee
Curaxys Sl
CURAXYS S L
Universidad de Cadiz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curaxys Sl, CURAXYS S L, Universidad de Cadiz filed Critical Curaxys Sl
Priority to ES201200465A priority Critical patent/ES2431914B2/es
Priority to PCT/ES2013/000062 priority patent/WO2013160498A1/es
Publication of ES2431914A1 publication Critical patent/ES2431914A1/es
Application granted granted Critical
Publication of ES2431914B2 publication Critical patent/ES2431914B2/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anticuerpo monoclonal humano anti-HER2.#La presente invención se refiere a un anticuerpo monoclonal humano que reconoce el dominio extracelular del receptor 2 del factor de crecimiento epidérmico humano (HER2) y es producido en células de retina embriónica humana. Asimismo, la presente invención se refiere al uso de dicho anticuerpo para medir el nivel de expresión de HER2 y para la preparación de un medicamento para el tratamiento de trastornos neoplásicos que cursan con la sobreexpresión de HER2.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
ES201200465A 2012-04-27 2012-04-27 Anticuerpo monoclonal humano ANTI-HER2 Expired - Fee Related ES2431914B2 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201200465A ES2431914B2 (es) 2012-04-27 2012-04-27 Anticuerpo monoclonal humano ANTI-HER2
PCT/ES2013/000062 WO2013160498A1 (es) 2012-04-27 2013-03-07 Anticuerpo monoclonal humano anti-her2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201200465A ES2431914B2 (es) 2012-04-27 2012-04-27 Anticuerpo monoclonal humano ANTI-HER2

Publications (2)

Publication Number Publication Date
ES2431914A1 ES2431914A1 (es) 2013-11-28
ES2431914B2 true ES2431914B2 (es) 2014-07-24

Family

ID=49482243

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201200465A Expired - Fee Related ES2431914B2 (es) 2012-04-27 2012-04-27 Anticuerpo monoclonal humano ANTI-HER2

Country Status (2)

Country Link
ES (1) ES2431914B2 (es)
WO (1) WO2013160498A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
KR20150043558A (ko) * 2004-07-22 2015-04-22 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
BRPI0812682A2 (pt) * 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CN103154035B (zh) * 2010-05-27 2017-05-10 根马布股份公司 针对her2的单克隆抗体

Also Published As

Publication number Publication date
WO2013160498A1 (es) 2013-10-31
ES2431914A1 (es) 2013-11-28

Similar Documents

Publication Publication Date Title
AR091545A1 (es) Anticuerpos anti-egfr y usos de los mismos
MY192843A (en) Antibodies specific for tgf-beta
ES2577860R1 (es) Determinación computerizada de refracción y astigmatismo
AR094403A1 (es) Terapia de combinación de anticuerpos anti-her3
AR103782A1 (es) ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHN
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
TR201910744T4 (tr) Büyüme ve farklılaşma faktörü 15 e (gdf-15) yönelik monoklonal antikorlar.
CL2015002567A1 (es) Compuestos y sus usos para modular la hemoglobina
CL2015000352A1 (es) Métodos de tratamiento de una tauopatía
BR112015027385A2 (pt) Anticorpos modificados de ligação ao fcrn humano e métodos de uso
AR088165A1 (es) Proteinas de funcion dual para tratar trastornos metabolicos
AR081427A1 (es) Metodo para preparar anticuerpos con propiedades mejoradas
JP2012017341A5 (es)
CU23953B1 (es) Anticuerpos neutralizantes de citomegalovirus humano
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
BR112013024574A2 (pt) polipeptídeo, uso, método de tratamento de indivíduos portadores de doenças e método de tratamento de indivíduos que possuem doenças com um polipeptídeo
WO2012059857A3 (en) Pan-her antibody composition
CO7131375A2 (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
AR088671A1 (es) Metodos para inhibir el crecimiento tumoral antagonizando el receptor de il-6
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
DOP2015000113A (es) 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona como un antagonista del receptor ampa dependiente de tarp-gamma 8
HK1250736A1 (zh) 用三種完全人類單克隆抗egfr抗體的組合治療具有表皮生長因子受體(egfr)的胞外結構域的突變的患者的方法
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
SMT201700098B (it) Aclidinio per l'uso nel miglioramento della qualità del sonno in pazienti con malattie respiratorie

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2431914

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20140724

FD2A Announcement of lapse in spain

Effective date: 20210915